ZA938171B - Conjugate vaccine against group B Streptococcus. - Google Patents

Conjugate vaccine against group B Streptococcus.

Info

Publication number
ZA938171B
ZA938171B ZA938171A ZA938171A ZA938171B ZA 938171 B ZA938171 B ZA 938171B ZA 938171 A ZA938171 A ZA 938171A ZA 938171 A ZA938171 A ZA 938171A ZA 938171 B ZA938171 B ZA 938171B
Authority
ZA
South Africa
Prior art keywords
streptococcus
vaccine against
conjugate vaccine
against group
group
Prior art date
Application number
ZA938171A
Other languages
English (en)
Inventor
James L Michel
Dennis L Kasper
Frederick M Ausubel
Lawrence C Madoff
Original Assignee
Gen Hospital Corp
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Brigham & Womens Hospital filed Critical Gen Hospital Corp
Publication of ZA938171B publication Critical patent/ZA938171B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ZA938171A 1992-11-02 1993-11-02 Conjugate vaccine against group B Streptococcus. ZA938171B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96886692A 1992-11-02 1992-11-02

Publications (1)

Publication Number Publication Date
ZA938171B true ZA938171B (en) 1995-03-07

Family

ID=25514876

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA938171A ZA938171B (en) 1992-11-02 1993-11-02 Conjugate vaccine against group B Streptococcus.

Country Status (14)

Country Link
EP (1) EP0669985A1 (fr)
JP (1) JPH08505282A (fr)
KR (1) KR100349331B1 (fr)
AU (1) AU689452B2 (fr)
CA (1) CA2146926A1 (fr)
FI (1) FI951979A (fr)
HU (1) HU220198B (fr)
IL (1) IL107458A0 (fr)
NO (1) NO951629L (fr)
NZ (1) NZ258684A (fr)
PL (1) PL177302B1 (fr)
RU (1) RU2209247C2 (fr)
WO (1) WO1994010317A2 (fr)
ZA (1) ZA938171B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015889A (en) * 1993-03-19 2000-01-18 Gunnar Lindahl Protein rib, a cell surface protein that confers immunity to many strains of the group B streptococcus: process for purification of the protein, reagent kit and pharmaceutical composition
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US6426074B1 (en) * 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
US7098182B2 (en) 1998-07-27 2006-08-29 Microbial Technics Limited Nucleic acids and proteins from group B streptococcus
CA2337102A1 (fr) * 1998-07-27 2000-02-10 Richard William Falla Le Page Acides nucleiques et proteines de streptococcus groupe b
US6890539B2 (en) 1998-12-22 2005-05-10 Microscience, Ltd. Genes and proteins, and their use
CN101486756A (zh) 1998-12-22 2009-07-22 微科学有限公司 外表面蛋白质及其基因和用途
GB9910375D0 (en) 1999-05-05 1999-06-30 Lindahl Gunnar Vaccine composition
WO2002031156A2 (fr) * 2000-10-13 2002-04-18 Shire Biochem Inc. Antigenes bvh-a2 et bvh-a3 du streptocoque du groupe b
AU2004220590B2 (en) * 2003-03-07 2010-02-18 Inhibitex, Inc. Polysaccharide - Staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
RU2487890C2 (ru) * 2007-04-16 2013-07-20 МинерваКС Апс Слитый белок, способный индуцировать защитный иммунитет против стрептококка группы в, и вакцина, содержащая такой белок
ES2413379T3 (es) * 2008-08-28 2013-07-16 Novartis Ag Presentación en la superficie celular de isoformas polipeptídicas mediante ultralectura de codón de terminación
RU2757426C2 (ru) 2015-10-21 2021-10-15 МинерваКС Апс Иммунногенный слитый белок
WO2017114655A1 (fr) 2015-12-30 2017-07-06 Minervax Aps Complexe immunogène provoquant une immunité protectrice contre un streptocoque du groupe b
CA3066020A1 (fr) 2017-06-16 2018-12-20 Glaxosmithkline Biologicals Sa Methode de traitement
CA3161857A1 (fr) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage et administration d'un vaccin a base de glycoconjugue de saccharide bacterien
EP4066854A1 (fr) 2021-03-29 2022-10-05 MinervaX Protéine de fusion immunogène

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302887B1 (fr) * 1986-04-16 1994-06-22 The Brigham And Women's Hospital, Inc. Antigenes, anticorps, vaccins bacteriens et leur procede de production
IL95578A (en) * 1989-09-15 1998-08-16 Gen Hospital Corp A vaccine made from polysaccharide and protein

Also Published As

Publication number Publication date
JPH08505282A (ja) 1996-06-11
HUT70981A (en) 1995-11-28
PL308555A1 (en) 1995-08-21
IL107458A0 (en) 1994-02-27
FI951979A (fi) 1995-06-29
CA2146926A1 (fr) 1994-05-11
HU220198B (hu) 2001-11-28
FI951979A0 (fi) 1995-04-26
NO951629L (no) 1995-07-03
KR950704492A (ko) 1995-11-20
NZ258684A (en) 1997-04-24
AU5665494A (en) 1994-05-24
AU689452B2 (en) 1998-04-02
NO951629D0 (no) 1995-04-28
EP0669985A1 (fr) 1995-09-06
PL177302B1 (pl) 1999-10-29
KR100349331B1 (ko) 2003-01-06
WO1994010317A2 (fr) 1994-05-11
RU2209247C2 (ru) 2003-07-27
WO1994010317A3 (fr) 1994-07-07

Similar Documents

Publication Publication Date Title
EP0634459A3 (fr) Formulations.
AU6858391A (en) Bundle tie
CZ197595A3 (en) Vaccine preparations
EP0597463A3 (en) Thermotherapiesonde.
EP0456063A3 (en) 1-h-3-aryl-pyrrolidin-2,4-dion-derivatives
EP0580285A3 (fr) Auto-réenclencheurs.
ZA926733B (en) 1,2-Dihydro-2-oxopyridines.
EP0604748A3 (fr) Manchon de trocart.
ZA938171B (en) Conjugate vaccine against group B Streptococcus.
ZA937034B (en) Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
EP0572808A3 (fr) Système de régulation antiblocage.
EP0468714A3 (en) Peptide-polysaccharide-protein conjugate vaccines
ZA927999B (en) Thickening agents.
EP0595970A4 (fr) Vaccin ameliore.
EP0599191A3 (fr) Circuit de régulation de vitesse d'un moteur.
EP0584212A4 (fr) Vaccins comprenant un polysaccharide encapsule dans un liposome.
EP0592354A3 (fr) Centrifugeuse à vide.
AU4970193A (en) IPNV vaccine
GB9320943D0 (en) Peptide-protein conjugate vaccines having anionic spacers
AU5626998A (en) Conjugate vaccine against group B Streptococcus
ZA939564B (en) Vaccines.
SG48106A1 (en) Pneumococcal polyaccharide conjugate vaccine
ZA93236B (en) Babesial rhoptry antigens.
EP0647139A4 (fr) VACCIN CONJUGUE ADHESINE-OLIGOSACCHARIDE CONTRE -i(HAEMOPHILUS INFLUENZAE).
ZA967198B (en) Vaccines.